{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:49:58Z","timestamp":1786992598129,"version":"build-2736575974"},"reference-count":51,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T00:00:00Z","timestamp":1723680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jhepr.2024.101190","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T06:38:23Z","timestamp":1724395103000},"page":"101190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-782X","authenticated-orcid":false,"given":"Claudia","family":"Campani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6803-3769","authenticated-orcid":false,"given":"Dimitrios","family":"Pallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3282-9254","authenticated-orcid":false,"given":"Sabrina","family":"Sidali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Giouleme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Grando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Nkontchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Demory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2489-0768","authenticated-orcid":false,"given":"Pierre","family":"Nahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7351-5027","authenticated-orcid":false,"given":"Nathalie","family":"Ganne-Carri\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-9353","authenticated-orcid":false,"given":"Jean-Charles","family":"Nault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jhepr.2024.101190_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101190_bib2","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"20","key":"10.1016\/j.jhepr.2024.101190_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101190_bib4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101190_bib5","first-page":"1","article-title":"Safety and efficacy of atezolizumab\/bevacizumab in patients with hepatocellular carcinoma and impaired liver function: a systematic review and meta-analysis","author":"Pasta","year":"2023","journal-title":"Liver Cancer"},{"issue":"10","key":"10.1016\/j.jhepr.2024.101190_bib6","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/jamaoncol.2023.3284","article-title":"Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis","volume":"9","author":"Xie","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101190_bib7","article-title":"Efficacy and safety of atezolizumab\/bevacizumab in patients with HCC after prior systemic therapy: a global, observational study","volume":"7","author":"Joerg","year":"2023","journal-title":"Hepatol Commun [Internet]"},{"key":"10.1016\/j.jhepr.2024.101190_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.dld.2024.02.018","article-title":"Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab","author":"Sultanik","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2024.101190_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.754858","article-title":"Serious adverse events reporting in phase III randomized clinical trials of colorectal cancer treatments: a systematic analysis","volume":"12","author":"Yao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101190_bib10","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1038\/s41598-021-85131-7","article-title":"A\u00a0systematic review and meta-analysis of treatment-related toxicities of curative and palliative radiation therapy in non-small cell lung cancer","volume":"11","author":"Or","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101190_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2024.101190_bib12","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"n71","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2024.101190_bib13","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma vs. other advanced solid tumours","author":"Celsa","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2024.101190_bib15","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-141-10-200411160-00009","article-title":"Better reporting of harms in randomized trials: an extension of the CONSORT statement","volume":"141","author":"Ioannidis","year":"2004","journal-title":"Ann Intern Med"},{"issue":"19","key":"10.1016\/j.jhepr.2024.101190_bib16","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archinternmed.2009.306","article-title":"Reporting of safety results in published reports of randomized controlled trials","volume":"169","author":"Pitrou","year":"2009","journal-title":"Arch Intern Med"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","article-title":"Adverse event reporting in cancer clinical trial publications","volume":"32","author":"Sivendran","year":"2014","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.jhepr.2024.101190_bib18","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/liv.15458","article-title":"A\u00a0history of variceal bleeding is associated with further bleeding under atezolizumab\u2013bevacizumab in patients with HCC","volume":"42","author":"Larrey","year":"2022","journal-title":"Liver Int"},{"issue":"17","key":"10.1016\/j.jhepr.2024.101190_bib19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101190_bib20","article-title":"Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors","volume":"2","author":"De Martin","year":"2020","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2014.03.030","article-title":"Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib","volume":"61","author":"Reig","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib22","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.29515","article-title":"Complete response under sorafenib in patients with hepatocellular carcinoma: relationship with dermatologic adverse events","volume":"67","author":"Rimola","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101190_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","article-title":"Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis","volume":"77","author":"El Hajra","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21873\/cdp.10012","article-title":"Initial experience of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in clinical practice","volume":"1","author":"Kuzuya","year":"2021","journal-title":"CDP"},{"issue":"9","key":"10.1016\/j.jhepr.2024.101190_bib25","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/hepr.13693","article-title":"Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria","volume":"51","author":"Sho","year":"2021","journal-title":"Hepatol Res"},{"issue":"16","key":"10.1016\/j.jhepr.2024.101190_bib26","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.3390\/cancers13163958","article-title":"Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice","volume":"13","author":"Ando","year":"2021","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s10637-021-01185-4","article-title":"Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice","volume":"40","author":"Hayakawa","year":"2022","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101190_bib28","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.3390\/curroncol28050352","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a predictive marker of response to atezolizumab plus bevacizumab for hepatocellular carcinoma","volume":"28","author":"Eso","year":"2021","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101190_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/hepr.13732","article-title":"Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: a multicenter analysis","volume":"52","author":"Chuma","year":"2022","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101190_bib30","first-page":"454","article-title":"Bevacizumab and atezolizumab for unresectable hepatocellular carcinoma: real-world data in taiwan-tainan medical oncology group H01 trial","volume":"37","author":"Lee","year":"2023","journal-title":"In\u00a0Vivo"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib31","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3390\/cancers14020343","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101190_bib32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/hepr.13771","article-title":"Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma","volume":"52","author":"Maesaka","year":"2022","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101190_bib33","first-page":"1899","article-title":"Combination of CRAFITY score with Alpha-fetoprotein response predicts a favorable outcome of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma","volume":"12","author":"Teng","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"3","key":"10.1016\/j.jhepr.2024.101190_bib34","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.5145","article-title":"Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve","volume":"12","author":"Tomonari","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.jhepr.2024.101190_bib35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/hepr.13836","article-title":"Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab\u2013bevacizumab treatment for hepatocellular carcinoma","volume":"53","author":"Ochi","year":"2023","journal-title":"Hepatol Res"},{"issue":"40","key":"10.1016\/j.jhepr.2024.101190_bib36","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030871","article-title":"Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: a multicenter prospective observational study","volume":"101","author":"Sugimoto","year":"2022","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101190_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11523-022-00921-x","article-title":"Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis","volume":"17","author":"Niizeki","year":"2022","journal-title":"Targ Oncol"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101190_bib38","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cncr.34559","article-title":"Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice","volume":"129","author":"Nakagawa","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2024.101190_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab vs. lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.jhepr.2024.101190_bib40","doi-asserted-by":"crossref","DOI":"10.1200\/GO.22.00205","article-title":"Efficacy, safety, and patient-reported outcomes of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in Thailand: a multicenter prospective study","author":"Charonpongsuntorn","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"24","key":"10.1016\/j.jhepr.2024.101190_bib41","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.3390\/cancers14246089","article-title":"Changes in ALBI score and PIVKA-II within three months after commencing atezolizumab plus bevacizumab treatment affect overall survival in patients with unresectable hepatocellular carcinoma","volume":"14","author":"Unome","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.jhepr.2024.101190_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221148541","article-title":"Atezolizumab plus bevacizumab in patients with child\u2013Pugh B advanced hepatocellular carcinoma","volume":"15","author":"Cheon","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jhepr.2024.101190_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1073133","article-title":"The effect of anti-PD-1\/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors vs. bevacizumab in unresectable hepatocellular carcinoma","volume":"14","author":"Zeng","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jhepr.2024.101190_bib44","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/hepr.13886","article-title":"The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis","volume":"53","author":"Matoya","year":"2023","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.jhepr.2024.101190_bib45","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jceh.2023.02.003","article-title":"Safety and efficacy of atezolizumab-bevacizumab in real world: the first Indian experience","volume":"13","author":"Kulkarni","year":"2023","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2024.101190_bib46","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3390\/cancers15051568","article-title":"Therapeutic modifications without discontinuation of atezolizumab plus bevacizumab therapy are associated with favorable overall survival and time to progression in patients with unresectable hepatocellular carcinoma","volume":"15","author":"Tokunaga","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101190_bib47","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/apt.17441","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort","volume":"57","author":"Jost-Brinkmann","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib48","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s10637-023-01349-4","article-title":"Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group","volume":"41","author":"Takaki","year":"2023","journal-title":"Invest New Drugs"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101190_bib49","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1093\/oncolo\/oyad090","article-title":"Association between immune-related adverse events and survival in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab","volume":"28","author":"Fukushima","year":"2023","journal-title":"The Oncologist"},{"issue":"7","key":"10.1016\/j.jhepr.2024.101190_bib50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/jgh3.12932","article-title":"Factors associated with the response to atezolizumab\/bevacizumab combination therapy for hepatocellular carcinoma","volume":"7","author":"Yano","year":"2023","journal-title":"JGH Open"},{"issue":"11","key":"10.1016\/j.jhepr.2024.101190_bib51","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s00535-023-02026-2","article-title":"Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal\u2013gastric varices","volume":"58","author":"Tada","year":"2023","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhepr.2024.101190_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hepr.13969","article-title":"Significance of the autoantibody assay in predicting the development of immune-related adverse events in\u00a0patients receiving atezolizumab plus bevacizumab combination therapy\u00a0for unresectable hepatocellular carcinoma","volume":"54","author":"Takada","year":"2024","journal-title":"Hepatol Res"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924001940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924001940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:08:04Z","timestamp":1755860884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924001940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2589555924001940"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101190","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneity in adverse events related to atezolizumab-bevacizumab for hepatocellular carcinoma reported in real-world studies","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101190"}}